UBI Ubisoft Entertainment SA

Ubisoft Announces its Global Creative Office

Ubisoft Announces its Global Creative Office

  
 
Ubisoft Announces its Global Creative Office



The new organization aims to further grow the value of Ubisoft’s brands by boosting game creation, delivery and fostering the autonomy of creative teams in studios
 



 







 
PARIS – October 6, 2022 – Today, Ubisoft is announcing the implementation of its Global Creative Office to better reflect and support its portfolio strategy. With this evolution, Ubisoft aims to further support creative teams by facilitating decision-making and strengthening the responsibility and autonomy of studios throughout the creative process. The overall goal is to boost creativity and ensure the highest level of quality in the execution and delivery of Ubisoft's games.



 



The new Creative Office will be structured around poles, moving away from a centralized organization to better support the key segments of Ubisoft’s portfolio strategy. Building on the Group’s vision, each pole will leverage its expertise to dive into the specificities of its audiences, game design and tech.



 



Chief Creative Officer Igor Manceau, who was instrumental in refining the group’s creative vision and in laying the foundations of this new organization, will leave Ubisoft for personal reasons at the end of November. In the meantime, Igor will continue refining the structure, in close collaboration with Marie-Sophie de Waubert, SVP of Studios, Martin Schelling, SVP of Production, Sandrine Caloiaro, Chief Portfolio Officer, Guillemette Picard, SVP of Production Technology and studio Managing Directors. Following Igor’s departure, Marie-Sophie will temporarily take over management of the Creative Office to ensure a smooth transition across teams and projects.



 



“In a fast-moving industry, it’s essential that we continue to adapt. I am grateful for Igor’s contribution to refining Ubisoft’s creative approach and for his commitment to bringing fresh ideas that level up the way we create,” said Yves Guillemot, CEO and Co-Founder, Ubisoft. “An exemplary leader, Igor has set the foundations for a new organization that will allow Ubisoft to successfully deliver on its content strategy, with new processes and clearer roles and responsibilities.”



 



"Over the last 24 years I got the chance to meet and work with talented and inspiring teams around the world. I am grateful for the opportunity to have taken part in this fantastic adventure.” Said Manceau. “I am confident in Ubisoft’s potential to continue surprising and delighting players for years to come”.

  

# # #

Contacts

Investor Relations

Jean-Benoît Roquette

SVP Investor Relations

39

Press Relations

Fabien Darrigues

Director of Global Communications

   

Alexandre Enjalbert

Senior Investor Relations Manager

78

About Ubisoft

Ubisoft is a creator of worlds, committed to enriching players’ lives with original and memorable entertainment experiences. Ubisoft’s global teams create and develop a deep and diverse portfolio of games, featuring brands such as Assassin’s Creed®, Brawlhalla®, For Honor®, Far Cry®, Tom Clancy’s Ghost Recon®, Just Dance®, Rabbids®, Tom Clancy’s Rainbow Six®, The Crew®, Tom Clancy’s The Division®, and Watch Dogs®. Through Ubisoft Connect, players can enjoy an ecosystem of services to enhance their gaming experience, get rewards and connect with friends across platforms. With Ubisoft+, the subscription service, they can access a growing catalog of more than 100 Ubisoft games and DLC. For the 2021–22 fiscal year, Ubisoft generated net bookings of €2,129 million. To learn more, please visit:

© 2022 Ubisoft Entertainment. All Rights Reserved. Ubisoft and the Ubisoft logo are registered trademarks in the US and/or other countries.

 

Attachment



EN
06/10/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ubisoft Entertainment SA

 PRESS RELEASE

Informations sur les droits de vote et les actions au 31 juillet 2025

Informations sur les droits de vote et les actions au 31 juillet 2025 Le 6 août 2025 Information relative au nombre total de droits de vote et d’actions composant le capital social   Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers Place de cotation :        Euronext ParisCompartiment :        Compartiment ACode ISIN :                FR0000054470Site web :                 Information mensuelle au 31 juillet 2025(Articles L. 233-8, II, du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Date Nombre total d’actions composant l...

Wedbush Research
  • Wedbush Research
UBI UBISOFT ENTERTAINMENT SA
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
WDC WESTERN DIGITAL CORPORATION
VYGR VOYAGER THERAPEUTICS INC.
TTWO TAKE-TWO INTERACTIVE SOFTWARE INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
RARE ULTRAGENYX PHARMACEUTICAL INC.
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NVCR NOVOCURE LTD.
NTAP NETAPP INC.
NBIX NEUROCRINE BIOSCIENCES INC.
MU MICRON TECHNOLOGY INC.
KURA KURA ONCOLOGY INC.
INTC INTEL CORPORATION
HURN HURON CONSULTING GROUP INC.
GME GAMESTOP CORP. CLASS A
GERN GERON CORP.
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
BZH BEAZER HOMES USA INC.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
AXTI AXT INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
CDR CD PROJEKT S.A.
INOD INNODATA
FRX_CN FENNEC PHARMACEUTICALS
7974 NINTENDO CO. LTD.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
EA ELECTRONIC ARTS INC.
CVCO CAVCO INDUSTRIES INC.
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
MRSN MERSANA THERAPEUTICS
ROKU ROKU INC. CLASS A
ISR ISORAY
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
UBER UBER TECHNOLOGIES INC.
STOK STOKE THERAPEUTICS
IGMS IGM BIOSCIENCES
IDYA IDEAYA BIOSCIENCES
PASG PASSAGE BIO
BDTX BLACK DIAMOND THERAPEUTICS
ACET ADICET BIO INC
KROS KEROS THERAPEUTICS
ITOS ITEOS THERAPEUTICS
ZNTL ZENTALIS PHARMACEUTICALS
LRMR LARIMAR THERAPEUTICS INC
PRAX PRAXIS PRECISION MEDICINES
U UNITY SOFTWARE
TVTX TRAVERE THERAPEUTICS INC
PLTR PALANTIR TECHNOLOGIES
VRDN VIRIDIAN THERAPEUTICS INC
IMNM IMMUNOME
PLTK PLAYTIKA HOLDING
RBLX ROBLOX
DAWN DAY ONE BIOPHARMACEUTICALS INC
STX SEAGATE TECHNOLOGY HLDGS PLC
ATXS ASTRIA THERAPEUTICS INC
GFS GLOBALFOUNDRIES INC
GMTX GEMINI THERAPEUTICS INC
VIGL VIGIL NEUROSCIENCE INC
TYRA TYRA BIOSCIENCES INC
EWTX EDGEWISE THERAPEUTICS INC
DDI DOUBLEDOWN INTERACTIVE CO LTD
APGE APOGEE THERAPEUTICS INC
SKLZ SKILLZ INC
EMBRAC B EMBRACER GROUP AB
DNTH DIANTHUS THERAPEUTICS INC
TLX TELIX PHARMACEUTICALS LIMITED
MAZE MAZE THERAPEUTICS INC
Pelham Smithers
  • Pelham Smithers

PSA Media & Entertainment: Have Video Games Got Too Expensive?

Burdened by higher costs, video game publishers are looking to raise prices. However, PSA’s gaming analyst Pelham Smithers points out that they are facing pushback, and may have to rethink.

Carole Braudeau
  • Carole Braudeau

Credit Morning 07/23/2025

Auchan: First-half sales are expected to fall by 3.3% in France (Olivier Dauvers)|Retail sales in France fell sharply in June, hit by the heatwave and one less Saturday.|ams OSRAM: € 500m private placement of new 2029 notes, preliminary Q2 figures in line|Unicredit withdraws its bid for Banco BPM and publishes strong Q2 results|

Carole Braudeau
  • Carole Braudeau

Morning Crédit 23/07/2025

Auchan : le chiffre d’affaires reculerait de -3,3% en France au S1 (Olivier Dauvers)|Forte baisse des ventes retail en France en juin, pénalisées par la canicule et un samedi de moins|ams OSRAM : placement privé de 500 m EUR d’obligations 2029, chiffres préliminaires au T2 en ligne|Unicredit renonce à son offre sur Banco BPM et publie de solides résultats T2|

ResearchPool Subscriptions

Get the most out of your insights

Get in touch